Retinol (vitamin A) is thought to exert its effects through the actions of its metabolite, all-trans-retinoic acid (ATRA), on gene transcription mediated by retinoic acid receptors (RAR) and retinoic acid response elements (RARE). However, retinoic acid resistance limits the chemotherapeutic potential of ATRA. We examined the ability of retinol to inhibit the growth of ATRA-sensitive (HCT-15) and ATRA-resistant (HCT-116, SW620, and WiDR) human colon cancer cell lines. Retinol inhibited cell growth in a dose-responsive manner. Retinol was not metabolized to ATRA or any bioactive retinoid in two of the cell lines examined. HCT-116 and WiDR cells converted a small amount of retinol to ATRA; however, this amount of ATRA was unable to inhibit cell growth. To show that retinol was not inducing RARE-mediated transcription, each cell line was transfected with pRARE-chloramphenicol acetyltransferase (CAT) and treated with ATRA and retinol. Although treatment with ATRA increased CAT activity 5-fold in ATRAsensitive cells, retinol treatment did not increase CAT activity in any cell line examined. To show that growth inhibition due to retinol was ATRA, RAR, and RARE independent, a pan-RAR antagonist was used to block RAR signaling. Retinol-induced growth inhibition was not alleviated by the RAR antagonist in any cell line, but the antagonist alleviated ATRA-induced growth inhibition of HCT-15 cells. Retinol did not induce apoptosis, differentiation or necrosis, but affected cell cycle progression. Our data show that retinol acts through a novel, RAR-independent mechanism to inhibit colon cancer cell growth. (Cancer Res 2005; 65(21): 9923-33) 
Introduction
Colorectal cancer is currently the third leading cause of death due to cancer in the United States. Retinoids, a group of compounds consisting of vitamin A (retinol), its natural metabolites, and several synthetic compounds, have been shown to act as cancer chemopreventive agents ( for reviews, see refs. 1-3). In rats, retinol, 9-cis-retinoic acid, and 4-(hydroxyphenyl)retinamide can inhibit the formation of carcinogen-induced aberrant crypt foci, a precursor to colon cancer, as well as colon tumors (4-7). Retinyl palmitate was recently shown to inhibit high-fat diet-induced aberrant crypt foci (7) . Additionally, several in vitro studies indicate that retinoids have potent antiproliferative effects on colon cancer cell lines and may hold potential for both chemoprevention and chemotherapy of colon cancer.
In almost all of the above studies, the retinoid examined has been an isoform of retinoic acid or a synthetic retinoid such as 4-(hydroxyphenyl)retinamide. Although these compounds are effective at inhibiting all-trans-retinoic acid (ATRA)-sensitive cell growth, the use of exogenous ATRA to study the effects of vitamin A assumes that all of the biological phenomena attributed to retinol are due to ATRA. The diet contains very little ATRA (8) . Rather, the diet contains vitamin A in two forms: (1) previtamin A carotenoids and (2) preformed vitamin A as retinol and retinyl esters. Retinyl esters are cleaved within the intestinal lumen to yield retinol. Therefore, human colonocytes are exposed primarily to retinol, the focus of this study. Within most cells, retinol is either esterified for storage or metabolized to ATRA. ATRA exerts its effects on cell growth and differentiation by binding to retinoic acid receptors (RAR) located in cell nuclei. RARs heterodimerize with retinoid X receptors (RXR) and bind to retinoic acid response elements (RARE) located in the regulatory regions of retinoidresponsive genes. When ATRA binds to the RAR member of the RAR/RXR heterodimer, gene transcription via RARE is induced ( for review, see ref. 2) .
Retinoic acid resistance is believed to be due to a defect in RARa, RARh, or RARg induction in response to ATRA ( for review, see refs. 2, 9-11). Retinoic acid resistance occurs when tumors or tumor-derived cell lines cease to growth inhibit or differentiate in response to treatment with ATRA. Retinoic acid resistance is a common phenomenon and appears to arise spontaneously in numerous types of cancer and tumor-derived cell lines. The defective receptor varies with cell line but RARh expression is frequently lost.
The objective of the present study was to determine if retinol could inhibit the growth of both ATRA-sensitive and ATRAresistant colon cancer cell lines in vitro. Because the ATRAresistant cell lines lack one or more RARs, their use allowed us to determine the effects of retinol on cell growth, exclusive of the effects of ATRA. Our data show that retinol itself inhibits the growth of both ATRA-sensitive and ATRA-resistant colon cancer cells through an ATRA-and RAR-independent mechanism.
atmosphere at 37jC with 5% CO 2 . All medium was supplemented with 10% FCS and antibiotics (1,000 units/mL penicillin and 1,000 Ag/mL streptomycin). The experiment was repeated with each cell line grown in either supplemented DMEM or McCoy's medium. Medium type did not affect cell growth. Cells were seeded in 12-well culture dishes at a density of 1 Â 10 4 cells per well. The following day, the medium was removed and replaced with medium containing 0, 0.1, 1, or 10 Amol/L ATRA or all-trans-retinol (Sigma, St. Louis, MO). All retinoids were prepared as 10 mmol/L stocks in 100% ethanol. All treatments, including control, received equal volumes of ethanol vehicle and all retinoid manipulations were performed in the dark. All treatments were done in duplicate. Cells were harvested using trypsin and counted via hemocytometer every 24 hours for 4 days.
Retinoid extraction and high-performance liquid chromatography analysis. To examine retinol metabolism, cells were seeded in 60 mm dishes at the following densities to yield 60% to 80% confluence and maximum high-performance liquid chromatography (HPLC) detection sensitivity at the time of harvest: 5 Â 10 5 cells/dish for 24 hours, 2. 16 hours, were used as a positive control for 4-oxoretinol production (13) . Retinoids were extracted and separated using a Waters Millennium HPLC system as described previously (14) .
Cell transfection and chloramphenicol acetyltransferase assays. To examine the possibility that an undetected metabolite of retinol was activating RAR/RXR-mediated transcription, all cell lines were transiently transfected with pRARE-chloramphenicol acetyltransferase (CAT; generously provided by Dr. Dianne Soprano). Cells were seeded onto 12-well plates at a density of 1.75 Â 10 5 cells/well and incubated overnight in FCS-supplemented medium. The following day, cells were transfected using LipofectAMINE 2000 (Promega, Madison, WI) according to the protocol of the manufacturer with 1 Ag of pRARE-CAT and 0.5 Ag of pSV-h-gal. Twentyfour hours later, the transfection medium was removed and the cells were treated with fresh medium containing 0, 1, and 10 Amol/L ATRA or retinol. The cells were harvested after treatment for 24 or 48 hours and assayed for h-galactosidase (h-Galactosidase Enzyme Assay System; Promega) and CAT (CAT Enzyme Assay System; Promega) activity as per instructions of the manufacturer. CAT activity was corrected for transfection efficiency using the h-galactosidase activity.
Retinoic acid receptor antagonist assays. To determine if retinol was inhibiting cell growth via RAR, the pan-RAR antagonist, AGN 193109 was used to block RAR function. The RAR pan-antagonist was synthesized by Detection of apoptosis. Nuclear staining via 4V ,6-diamidino-2-phenylindole (DAPI) and flow cytometry analysis, described below, were used to determine if cell growth inhibition was due to apoptosis. For DAPI staining, cells were plated at 1 Â 10 4 cells per well in 12-well plates before treatment with 0, 1, and 10 Amol/L retinol. Cells incubated for 4 hours at 37jC with 4 Ag/mL camptothecin served as the positive control for apoptosis. Both adherent and floating cells were harvested every 24 hours for 4 days. The cells were centrifuged and washed with PBS to remove all traces of media. Cells were then incubated with 2 Ag/mL DAPI for 10 minutes at 37jC before counting at 400Â magnification with an Olympus upright fluorescence microscope. To obtain cell counts, at least three different locations on each slide were used. Two hundred cells were counted at each location yielding a minimum of 600 cells counted per slide. Cells with segmented nuclei were scored as apoptotic.
Cellular differentiation. Alkaline phosphatase activity was used to determine if retinol was inhibiting cell growth by inducing cellular differentiation. All cell lines were plated on 60 mm dishes at a density of 5 Â 10 4 cells per plate. Twenty-four hours later, cells were treated with 0, 1, and 10 Amol/L retinol or 2 mmol/L sodium butyrate (positive control) for 96 hours. Alkaline phosphatase activity was determined as described previously (15) . Alkaline phosphatase activity was measured by the conversion of p-nitrophenyl phosphate (19.8 mmol/L) to p-nitrophenol by 0.1 mL of cell lysate in 100 mmol/L glycine buffer, containing 1 mmol/L MgCl 2 (pH 10). Alkaline phosphatase enzyme activity was corrected for lysate protein content and expressed as percentage positive control.
Necrosis assays. Trypan blue exclusion assays were used to measure cell death. Briefly, an aliquot of the cells harvested for the growth curve assays was pelleted by centrifugation, resuspended in 0.5 mL HBSS, and incubated with an equal volume of 0.4% trypan blue solution (Sigma-Aldrich, St. Louis, MO) for 5 minutes at room temperature before counting with a hemocytometer. Blue cells were scored as necrotic.
Flow cytometry analysis. To determine if growth inhibition was due to cell cycle arrest and to confirm the absence of apoptosis through lack of a sub-G 1 peak, cells were seeded on 60 mm dishes at a density of 3 Â 10 5 (HCT15 and SW620) or 2 Â 10 5 (HCT-116 and WiDR) cells per dish to provide 50% to 60% confluence at the time of harvest. To synchronize, cells were plated in serum-free medium for 24 hours and treated with 1 (HCT-15) or 3 Ag/mL (HCT-116, SW620, WiDR) aphidicholin for an additional 24 hours. The following day, the cells were washed with PBS and treated with fresh FCS-supplemented media containing 0, 1, and 10 Amol/L retinol. Cells were harvested, fixed in 70% ethanol overnight, and stained with 40 Ag/mL propidium iodide as described previously (16) . At least 10,000 cells were analyzed per sample using a FACSCalibur machine (Becton Dickinson, San Jose, CA). DNA content was determined using Modfit software version 3.0 (Verity Software House, Inc., Topsham, ME).
Results
Growth of all-trans-retinoic acid-resistant colon cancer cells is inhibited by retinol. The ability of retinol to inhibit cell growth was examined in three ATRA-resistant human colon cancer cell lines HCT-116 (17), SW620 (18) , and WiDR (11) . An ATRAsensitive cell line, HCT-15, was chosen to serve as a positive control for the inhibitory effects of ATRA on colon cancer cell growth (19) . Serum concentrations of retinol range from 0.5 to 2 Amol/L (20) . Therefore, 0.1 Amol/L was selected to represent a subphysiologic, and 1 Amol/L a physiologic, concentration of retinol. The highest level, 10 Amol/L retinol, was used as a pharmacologic, but potentially therapeutically relevant, concentration. There is very little ATRA (4-14 nmol/L) in the serum (21, 22) . ATRA levels were chosen to match the concentrations of retinol used and to reflect ATRA levels commonly found in the literature (9) (10) (11) 23) .
After 96 hours of treatment, the growth of HCT-15 cells was inhibited by ATRA ( Fig. 1A) as expected. In addition, HCT-15 cell growth was also inhibited by retinol in a dose-responsive manner. Cells treated with 10 Amol/L retinol exhibited the largest degree of inhibition to 36.7 F 7.8% of control. HCT-116 cell growth was inhibited slightly by 0.1 and 1 Amol/L retinol but this decrease was not significant when compared with the same concentrations of ATRA (Fig. 1B) . However, HCT-116 cell growth was significantly inhibited by 10 Amol/L retinol (37.5 F 9.2% of control) when compared with 10 Amol/L ATRA (74.3 F 4.7% of control). SW620 and WiDR cell growth was significantly inhibited by treatment with 0.1 and 1 Amol/L retinol for 96 hours when compared with ATRA (Fig. 1C and D) , indicating that physiologic levels of retinol can inhibit the growth of ATRA-resistant cells. At 10 Amol/L concentrations, there was no significant difference in the ability of ATRA and retinol to inhibit SW620 and WiDR cell growth. The highest concentration of ATRA, 10 Amol/L, inhibited cell growth slightly in all cell lines examined (Fig. 1) . These data show that retinol can inhibit the growth of both ATRA-sensitive and ATRAresistant colon cancer cells.
Retinol is not metabolized to bioactive compounds. To determine if retinol was metabolized to a bioactive compound, such as ATRA, anhydroretinol, or 4-oxoretinol, we performed reverse-phase HPLC on all cell lines as described previously (14 Retinol does not induce retinoic acid response elementchloramphenicol acetyltransferase reporter gene expression. To confirm that retinol was not metabolized to a bioactive compound that could transactivate RARE-mediated gene transcription, each colon cancer cell line was transiently transfected with pRARE-CAT and treated with ATRA or retinol. The pRARE-CAT construct contains only the nucleotides corresponding to the RARE found in the regulatory region of the RARh2 gene linked to a CAT promoter. Figure 3A shows that treatment of ATRA-sensitive HCT-15 cells with both 1 and 10 Amol/L ATRA for 24 or 48 hours resulted in an increase in CAT activity to 4.98 F 0.39-fold over control at 48 hours for cells treated with 10 Amol/L ATRA. Because HCT-15 cells were ATRA sensitive, we were surprised to find that treatment of HCT-15 cells with retinol did not increase CAT activity to >1.80 F 0.06-fold over control at 48 hours for cells treated with 1 Amol/L retinol (Fig. 3A) . However, this lack of CAT activity reflects the metabolism data ( Fig. 2A-D) , showing that HCT-15 cells do not metabolize retinol to ATRA.
Neither ATRA nor retinol increased CAT activity >1.7-fold over control in any of the three ATRA-resistant colon cancer cell lines (Fig. 3B-D) . The lack of CAT activity in cells treated with ATRA confirms the inability of these cells to respond to ATRA via RAR/ RARE-mediated mechanisms as described previously (11, 17, 18 (Fig. 2) and the lack of CAT activity in SW620 cells when treated with retinol both confirms the metabolism data and shows that an RAR-activating metabolite of retinol is either not present or is incapable of activating RAR/ RARE-mediated gene transcription. In summary, the inability of retinol to increase CAT activity in any of the cell lines examined, including ATRA-sensitive HCT-15 cells, shows that retinol is not inducing retinoic acid-mediated gene transcription, confirming our metabolism data, and indicating that retinol may be acting exclusive of the RAR to inhibit colon cancer cell growth.
Retinol is not acting through retinoic acid receptors to inhibit cell growth. To confirm that the growth inhibition exhibited by cells treated with retinol was not mediated by the retinoic acid/RAR/RARE retinoid signaling mechanism, all cell lines were treated with a RAR pan-antagonist, AGN 193109. This antagonist, when added at 10 times the concentration of agonist, blocks the ability of agonist to bind to RAR (25) (Fig. 4) . The inability of AGN 193109 to block retinol-induced growth inhibition confirms the results of the metabolism and RARE reporter experiments, which also indicate that retinol is not acting via retinoic acid/RAR/RARE Figure 2 . Retinol is not metabolized to bioactive compounds in HCT-15 and SW620 cells but is converted to retinoic acid by HCT-116 and WiDR cells. Cells were plated and allowed to attach for 24 hours before addition of medium containing 0, 1, or 10 Amol/L retinol. Cells were allowed to grow for 24, 48, 72, or 96 hours before the medium was removed and replaced with new medium containing 5% FCS and 50 nmol/L [ 3 H]retinol. The concentration of nonradioactive retinol in 5% FCS was %50 nmol/L (14) . Cells were allowed to incubate for another 2, 4, 8, or 16 hours before harvest. The retinoids were extracted from cell and medium samples and separated by HPLC as described (14) . Data shown represent radiolabeled retinoids extracted from medium (A ) or cells (B ) of the indicated cell lines 48 hours after treatment with 0 or 10 Amol/L retinol followed by incubation for 8 hours with 50 nmol/L [ 3 H]retinol. The identities of the retinoids were determined by coelution with known nonradiolabeled (cold) standards included in the samples. Changes in absorbance are recorded as changes in voltage by the FloOne software that generated these chromatographs and controls the liquid scintillation counter. Thus, the unit for the y -axis of ''Standards'' panel is volts. The slight difference in elution time between the cold standards and the 3 H peaks is due to the transit time from the photodiode array to the scintillation counter. to affect cell growth even in the ATRA-sensitive, HCT-15 cell line. Unlike the ATRA-resistant cell lines, HCT-15 cells contain all of the cellular machinery required for induction of ATRA/RAR/RAREmediated gene transcription and growth inhibition (11) . As shown in Fig. 4A , ATRA is acting via this mechanism to inhibit the growth of HCT-15 cells. In contrast, retinol is acting via a novel, receptorindependent mechanism to inhibit the growth of both ATRAresistant and, surprisingly, ATRA-sensitive human colon cancer cell lines.
Retinol does not induce apoptosis, differentiation, or necrosis in all-trans-retinoic acid-resistant colon cancer cells. To determine the mode by which retinol inhibits the growth of colon cancer cells, apoptosis was examined by nuclear staining using DAPI (Fig. 5, left) and fluorescence-activated cell sorting (FACS) analysis of DNA content (Fig. 6) . The percentage of DAPIstained cells exhibiting segmented nuclei was <10% in all cell lines at all time points and treatments examined. FACS analysis failed to detect a sub-G 1 peak in any of the cell lines when treated with retinol, confirming the absence of apoptosis (Fig. 6 ). In addition, in all cell lines, <4% apoptosis was detected with TUNEL assay and no apoptosis was detected by poly(ADP)-ribose polymerase (PARP) cleavage or DNA laddering (data not shown). Therefore, retinol does not inhibit colon cancer cell growth by inducing apoptosis.
Alkaline phosphatase assays were performed to determine if retinol was inhibiting colon cancer cell growth by inducing cellular differentiation. Retinol does not induce alkaline phosphatase activity in HCT-116, SW620, or WiDR cells (Fig. 5, right) . Retinol increased alkaline phosphatase activity slightly in HCT-15 cells (Fig. 5A) . In contrast, treatment with sodium butyrate resulted in a large increase in alkaline phosphatase activity in each cell line. These data indicate that retinol is not inhibiting cell growth by inducing cellular differentiation in the three ATRA-resistant cell lines. A small increase in alkaline phosphatase activity in HCT-15 cells treated with retinol may indicate that cellular differentiation accounts for part of the retinol-induced decrease in growth.
To ensure that retinol was not inducing necrosis, trypan blue dye exclusion assays were performed on the adherent cells used for the growth curve experiments described in Fig. 1 . The percentage of cells that stained with trypan blue dye varied between 0.1% and 7% and no consistent pattern was exhibited under any treatment condition at any time point (data not shown). Therefore, necrosis is not responsible for the growth inhibition exhibited by colon cancer cells treated with retinol.
Retinol affects cell cycle progression. Treatment with 10 Amol/L retinol increased the percentage of cells in G 0 -G 1 while decreasing the percentage of cells in S phase in the HCT-15, SW620, and WiDr cell lines (Fig. 6A, C, and D) . (Fig. 6B) , but retinol decreased the percentage of HCT-116 cells in S phase. As can be seen in Fig. 1D , control HCT-116 cells continued to divide in a linear manner, whereas HCT-116 cells treated with 10 Amol/L retinol ceased to divide between 24 and 48 hours of treatment. This result, when considered in light of the absence of apoptosis, differentiation, and necrosis in the HCT-116 cell line despite strong growth inhibition by retinol, may indicate that retinol acts to slow the overall rate of cell division and increase the generation time of this cell line.
Discussion
This study shows that retinol inhibits the growth of both ATRAsensitive and ATRA-resistant human colon cancer cell lines. We provide three lines of evidence that retinol is acting independent of the established ATRA/RAR/RARE retinoid signaling pathway. The first line of evidence indicates that retinol is not metabolized to bioactive compounds, such as ATRA, in two of the four cell lines examined. The remaining two cell lines synthesized only small amounts of ATRA from retinol. Second, we show that retinol does not activate RARE-mediated gene transcription. Finally, we present evidence that a RAR antagonist blocks the ability of ATRA to inhibit the growth of ATRA-sensitive HCT-15 cells, as expected, but does not block the ability of retinol to inhibit the growth of any cell line examined. The most surprising outcome of this study is that retinol is not acting through a RAR-dependent pathway in ATRAsensitive HCT-15 cells. Therefore, even in the presence of functioning RAR, retinol does not inhibit cell growth by the actions of its metabolite ATRA, because this metabolite is not present in ATRA-sensitive HCT-15 cells (Fig. 2) . The ability of retinol to inhibit colon cancer cell growth is particularly interesting given that colon cancer cell lines produce little or no ATRA (Fig. 2) . This finding is supported in a recent study by Jette et al. (26) that used Northern blot analysis to show that colon cancer cell lines, including HCT-116, lack retinol dehydrogenases 5 and L, and therefore the ability to synthesize ATRA. The metabolism of retinol by colon cancer cells was not examined in the study by Jette et al. (26) . In contrast, our data shows that the HCT-116 cell line is capable of synthesizing very small amounts of ATRA from retinol (Fig. 2) . This discrepancy is perhaps due to the ability of HPLC to detect extremely small amounts of [ 3 H]retinoids compared with the relative lack of sensitivity of Northern blot analysis.
4-Oxoretinol and anhydroretinol are two naturally occurring retinoids capable of inhibiting cell growth. 4-Oxoretinol acts via RARs (13), much like ATRA, whereas anhydroretinol acts via a receptor-independent cytosolic mechanism to inhibit cell growth To measure apoptosis (left), floating and adherent cells were harvested every 24 hours, centrifuged, and washed with PBS to remove all traces of media. Cells were stained with 2 Ag/mL DAPI for 10 minutes in 37jC before observation. To measure cellular differentiation (right ), cells were plated as described and treated with 0, 1, or 10 Amol/L retinol or 2 mmol/L sodium butyrate for 96 hours. Alkaline phosphatase activity was determined as described (15) by the conversion of p-nitrophenyl phosphate to p-nitrophenol at 410 nm. Alkaline phosphatase enzyme activity is expressed as percentage positive control. Columns, mean for three independent experiments; bars, SE. (27, 28) . Neither compound was formed from retinol by any of the cell lines we examined (Fig. 2) . We cannot eliminate the possibility that an unknown bioactive metabolite of retinol was formed that existed only briefly or was not detected by our HPLC protocol. However, the inability of retinol to induce CAT activity in cells transfected with a pRARE-CAT construct (Fig. 3) as well as the inability of a pan-RAR antagonist to block the effects of retinol on cell growth (Fig. 4) support the metabolism data.
We chose to use the pan-RAR antagonist, AGN 193109, to block RARs because this compound exhibits a high affinity for RAR (25) . Although a genetic approach would have been more specific, the dominant-negative RAR construct available is activated by retinol (29) , making it inappropriate for this study. Therefore, we included a positive control, showing that AGN 193109 blocks ATRA-induced growth inhibition in the HCT-15, ATRA-sensitive cell line (Fig. 3A) , to indicate that AGN 193109 is functioning to block RAR-mediated growth inhibition.
Retinoids have been previously shown to inhibit cancer cell growth by increasing cellular differentiation, inducing apoptosis, or causing cell cycle arrest. With respect to colon cancer, retinoids tend to induce tumor apoptosis both in vitro (11, 30, 31) and in vivo (4, 32, 33) . The cell lines examined in this study showed no apoptosis in response to retinol treatment (Figs. 5, left, and 6 ). In contrast, retinol induced G 0 -G 1 arrest in three of the cell lines examined (Fig. 6) . Although retinol failed to increase the percentage of cells in G 0 -G 1 in the HCT-116 cell line, growth inhibition in these cells could be due to an overall increase in generation time because retinol does decrease cell growth (Fig. 1B) . The differing responses between the HCT-116 cell line and the other three may reflect the heterogenicity of these cell lines, tumor stage (carcinoma versus adenoma), and presence or absence of various proteins in each cell line, e.g., adenomatous polyposis coli or p53.
Retinoids tend to induce cell cycle arrest by blocking the G 1 -S phase transition ( for review, see ref. 1). Unfortunately, the effect of retinoids on cell cycle regulatory proteins seems to be cell type specific (1) . For example, in carcinogen-exposed immortalized human bronchial epithelial cells, ATRA-induced G 1 arrest is associated with decreased cyclin D1 protein levels due to ubiquitin-mediated degradation of cyclin D1 (34, 35) . In contrast, ATRA-induced G 1 arrest in MCF-7 breast cancer cells is associated with decreased pRB phosphorylation, whereas cyclin D1, p21 WAF1/CIP1 , cdk4, and cdk6 activity either does not change or decreases slightly, depending on the study (36) (37) (38) .
This study shows that retinol is acting independent of the RAR to inhibit colon cancer cell growth. Previously, retinoids have been shown to exert their receptor-independent effects via interactions with protein kinase Ca (39), F-actin (40), c-Raf kinase (28) , regulating mitochondrial membrane potential (41) , generating reactive oxygen species (42) , increasing intracellular ceramide levels (43) , activating c-Jun NH 2 -terminal kinase (44) , inducing ubiquitin-dependent proteolysis (34, 35) , and affecting mitogenactivated protein kinase (45, 46) , phosphatidylinositol 3-kinase (PI3K)/Akt (47) , and epidermal growth factor receptor signaling (48) . The Hammerling lab has shown that the retroretinoids, retinol, and ATRA can bind protein kinase Ca and affect its redox activation (39) . In contrast to our present study, they speculate that retinol antagonizes anhydroretinol and increases cell survival by binding to c-Raf and augmenting its response to reactive oxygen species generated during UV irradiation; however, the link between cell growth and c-Raf activation was not directly examined (28) . Because anhydroretinol induces apoptosis, we do not expect retinol to affect cell growth by interacting with c-Raf or any of the other pathways listed above that induce apoptosis.
In conclusion, this study shows that retinol acts through a novel mechanism to inhibit the growth of both ATRA-sensitive and ATRA-resistant colon cancer cells by affecting cell cycle progression. Resistance to ATRA is a common phenomenon and limits the use of retinoic acid derivatives as chemotherapy. We speculate that retinol, or a derivative of it, may prove an effective therapy to treat colorectal cancer.
